First Pacific Financial Buys 1,418 Shares of Pfizer Inc. (NYSE:PFE)

First Pacific Financial grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 7.3% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 20,716 shares of the biopharmaceutical company’s stock after buying an additional 1,418 shares during the period. First Pacific Financial’s holdings in Pfizer were worth $596,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in PFE. Worth Asset Management LLC acquired a new stake in shares of Pfizer in the first quarter valued at $29,000. Briaud Financial Planning Inc bought a new position in shares of Pfizer in the third quarter worth about $30,000. Sanctuary Wealth Management L.L.C. acquired a new position in shares of Pfizer during the fourth quarter worth approximately $50,000. Mizuho Securities Co. Ltd. acquired a new stake in shares of Pfizer in the third quarter valued at approximately $34,000. Finally, VisionPoint Advisory Group LLC raised its position in Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on PFE shares. TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research note on Thursday, January 4th. Barclays dropped their target price on shares of Pfizer from $34.00 to $28.00 and set an “equal weight” rating for the company in a research report on Thursday, December 14th. Guggenheim began coverage on Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Friday, March 1st. Twelve equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $36.88.

Pfizer Stock Up 0.7 %

Shares of PFE stock opened at $27.77 on Thursday. Pfizer Inc. has a 52-week low of $25.61 and a 52-week high of $42.22. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The stock has a market cap of $157.25 billion, a price-to-earnings ratio of 77.14, a PEG ratio of 1.24 and a beta of 0.61. The firm’s 50-day moving average is $27.47 and its 200-day moving average is $29.47.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. During the same quarter in the prior year, the business earned $1.14 EPS. The firm’s revenue for the quarter was down 41.3% on a year-over-year basis. Sell-side analysts predict that Pfizer Inc. will post 2.22 EPS for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.